Real-world analysis of HER2-ultralow in HR+/HER2- metastatic breast cancer: prevalence and first-line chemotherapy outcomes.

Ther Adv Med Oncol · 2025 · PMC12477358 · PMID 41031207

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

10 Similarly, in a study of 1024 surgical patients, HER2-ultralow showed a nonsignificant trend toward better OS and DFS compared to HER2-low, with noted clinicopathologic differences. 19 The prognostic impact of low HER2 expression in breast cancer is still being studied, with current evidence showing mixed results.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.